REMS
Aspergillus
andCandida
infections in patients who are severely immunocompromised, such as hematopoietic stem cell transplant recipients with graft-versus-host disease or those with hematologic malignancies with prolonged neutropenia from chemotherapy (tablets, oral suspension, delayed-release oral suspension, and injection).Spectrum:
Absorption: Well absorbed following oral administration; absorption is optimized by food; IV administration results in complete bioavailability.
Distribution: Extensive extravascular distribution and penetration into body tissues.
Protein Binding: >98%.
Half-Life: 35 hr.
(plasma concentrations)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO (suspension) | unknown | 35 hr | 8 hr |
PO-ER | unknown | 45 hr | 24 hr |
IV | unknown | 2 hr | 24 hr |
Contraindicated in:
Use Cautiously in:
CV: QT interval prolongation, TORSADES DE POINTES
Endo: adrenal insufficiency
F and E: hypokalemia, hypomagnesemia, hypocalcemia
GI: diarrhea, nausea, vomiting, HEPATOCELLULAR DAMAGE, PANCREATITIS
Neuro: headache
Resp: cough
Misc: fever, HYPERSENSITIVITY REACTIONS
Drug-drug:
Treatment of Invasive Aspergillosis
Prophylaxis of Invasive Aspergillus and Candida Infections
Treatment of Oropharyngeal Candidiasis
Lab Test Considerations:
IV Administration: